Héma-Québec Seroprevalence Study

Overview

Acronym
HQ
Website
HQ
Investigators
  • Dr. Marc Germain

    Hema-Quebec

Contacts
  • Dr. Marc Germain

    Hema-Quebec

General Design

Study design
Cohort
Start Year
2020
General Information on Follow Up (profile, frequency)
In order to continue monitoring the evolution of COVID-19 in Quebec, the study may be repeated at regular intervals until the end of the pandemic. The first follow-up will begin in January 2021 and will continue over a 7-week period in the context of the second wave of the pandemic.
Recruitment Target
  • Individuals
Number of Participants
7,691
Number of Participants with Biological Samples
7,691

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Timeline

Population

HQ population

Selection Criteria

Minimum age
18
Maximum age
81
Countries
  • Canada
Territory
Quebec
Health Status
  • Being eligible for regular blood donation (good health)
Other Criteria
Exclusion: symptoms of COVID-19 in the last 14 days prior to their donation

Sources of Recruitment

Specific Population
  • Other specific population : Blood donors
Supplementary Information
The participants of this seroprevalence study were regular blood donors who completed their donation between May 25 and July 9 2020.

Sample Size

Number of Participants
7,691
Number of Participants with Biological Samples
7,691

Data Collection Events

# Name Description Start End
0 HQ - Wave 1 2020 (May) 2020 (July)
1 HQ - Nested case-control study 2020 (May) 2020 (July)
2 HQ - Wave 2 2021 (January) 2021 (March)

Individual Studies Included

Acronym Name Study design Participants Countries

Harmonization Projects Included

Acronym Name

Networks

Acronym Name Studies

Datasets

Name Type Data Collection Events Variables
Last Update: 2021-04-23 17:22